PCR-RFLP detection of PAI-2 gene variants: prevalence in ethnic groups and disease relationship in patients undergoing coronary angiography
Foy, C.A.; Grant, P.J.
Thrombosis and Haemostasis 77(5): 955-958
1997
ISSN/ISBN: 0340-6245 PMID: 9184409 Document Number: 477160
PAI-2 is a fibrinolytic inhibitor produced predominantly by monocytes. Most PAI-2 is intracellular making study in clinical conditions difficult. Abnormalities in production may be associated with inflammation and fibrinolysis at sites of tissue damage such as the atherosclerotic plaque. PAI-2 gene variants have been described: variant A consists of Asn-120, Asn-404 and Ser-413 and variant B consists of Asp-120, Lys-404 and CyS-413. We designed a PCR-RFLP assay using primers spanning the region containing Asn/Lys-404 and Ser/Cys-413. Variant B contains an MwoI restriction site. We analysed 302 Pima Indians and 286 healthy Caucasian volunteers. To investigate relationships between genotype and vascular disease we analysed 333 Caucasian patients undergoing coronary angiography. Gene variant B was more common in the Pimas than in Caucasians (p lt 0.0001). There was no significant difference in genotype distribution between the volunteers and patients. In the patients there was no association between genotype and either a history of MI or extent of coronary atheroma.